A multicenter, open-label study to evaluate the safe and effective use of a new electromechanical auto-injection device for self-injection of certolizumab pegol

References

• Udalova I, Monaco C, Nanchahal J, et al. Anti-TNF therapy. Microbiol Spectr. 2016;4(4):MCHD-0022-2015.
   PubMed Web of Science ®Google Scholar
• Giacomelli R , Afeltra A, Alunno A, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16(9):911–924.
   PubMed Web of Science ®Google Scholar
• Schwartzman S, Morgan GJ Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther. 2004;6(Suppl 2):S19–23.
   PubMed Web of Science ®Google Scholar
• Sylwestrzak G, Liu J, Stephenson JJ, et al. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits. 2014;7(2):71–81.
   PubMedGoogle Scholar
• Domanska B, Stumpp O, Poon S, et al. Using patient feedback to optimize the design of a certolizumab pegol electromechanical self-injection device: insights from human factors studies. Adv Ther. 2018;35(1):100–115.
   PubMed Web of Science ®Google Scholar
• van den Bemt BJF, Gettings L, Domańska B, et al. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384–392.
   PubMed Web of Science ®Google Scholar
• Larsson I, Bergman S, Fridlund B, et al. Patients’ independence of a nurse for the administration of subcutaneous anti-TNF therapy: A phenomenographic study. Int J Qual Stud Health Well-being. 2010;5. DOI:10.3402/qhw.v5i2.5146.
   PubMed Web of Science ®Google Scholar
• Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases–focusing on work productivity and disability. J Rheumatol Suppl. 2011;88:55–61.
   PubMedGoogle Scholar
• Giacomelli R, Gorla R, Trotta F, et al. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology (Oxford). 2015;54(5):792–797.
   PubMed Web of Science ®Google Scholar
• Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the self-injection assessment questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9:2.
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Toth E, Schiff M, et al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences. Adv Ther. 2018;35(9):1333–1355.
   PubMed Web of Science ®Google Scholar
• Bluett J, Morgan C, Thurston L, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the biologics in rheumatoid arthritis genetics and genomics study syndicate cohort. Rheumatology (Oxford). 2015;54(3):494–499.
   PubMed Web of Science ®Google Scholar
• Bayas A, Ouallet JC, Kallmann B, et al. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv. 2015;12(8):1239–1250.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Cimzia assessment report. 2018 [cited 2020 April 15]. Available from: https://www.ema.europa.eu/en/documents/variation-report/cimzia-h-c-1037-ii-0065-epar-assessment-report-variation_en.pdf
   Google Scholar
• European Medicines Agency. Cimzia summary of product characteristics. 2018 [cited 2020 April 15]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf
   Google Scholar
• United States Food and Drug Administration , Cimzia prescribing information. 2018 [cited 2020 April 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125160s283lbl.pdf
   Google Scholar
• Schiff M, Saunderson S, Mountian I, et al. Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment. Rheumatol Ther. 2017;4(2):445–463.
   PubMed Web of Science ®Google Scholar
• Duruoz MT, Poiraudeau S, Fermanian J, et al. Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap. J Rheumatol. 1996;23(7):1167–1172.
   PubMed Web of Science ®Google Scholar
• Poiraudeau S, Lefevre-Colau MM, Fermanian J, et al. The ability of the Cochin rheumatoid arthritis hand functional scale to detect change during the course of disease. Arthritis Care Res. 2000;13(5):296–303.
   PubMed Web of Science ®Google Scholar
• Pouls B, Kristensen LE, Petersson M, et al. A pilot study examining patient preference and satisfaction for ava, a reusable electronic injection device to administer certolizumab pegol. RMD Open. 2019 ;doi: 10.1080/17425247.2020.1736552.
   Google Scholar
• Schulze-Koops H , Giacomelli R, Samborski W, et al. Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(2):201–208.
   PubMed Web of Science ®Google Scholar
• Sheikhzadeh A, Yoon J, Formosa D, et al. The effect of a new syringe design on the ability of rheumatoid arthritis patients to inject a biological medication. Appl Ergon. 2012;43(2):368–375.
   PubMed Web of Science ®Google Scholar
• Boeri M, Szegvari B, Hauber B, et al. From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices. Patient Prefer Adherence. 2019;13:1093–1110.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28(10):1619–1629.
   PubMed Web of Science ®Google Scholar